Fundacion Instituto Leloir

Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet)

Inis Biotech LLC

Cti S.a.

Comision Nacional De Energia Atomica (Cnea)

Osvaldo Podhajcer

Manuel Gidekel

Yuti Chernajovsky

Jose Mordoh

Alicia Ines Bravo

Helga Weber

Maria Veronica Lopez

Diego Luis Viale

Maria Fernanda Ledda

Lucia Policastro

Soraya Karina Adris

Hebe Duran

Eduardo Cafferata

Eduardo Gustavo Alfredo Cafferata

This invention is related to the field of cancer treatment, more specifically to gene therapy in combination with a suitable chemotherapeutic agent. The present invention is related to a new oncolytic virus, which is able to inhibit the growth of malignant tumors or is a treatment of hyperproliferative mammalian cells, or is a treatment of cancer. The oncolytic virus works in combination with a suitable chemotherapeutic agent. More specifically, the present invention provides a pharmaceutical kit comprising an oncolytic adenovirus and a chemotherapeutic agent, and a method for the treatment of cancer.

Pharmaceutical kit and method for treating cancer

The invention provides promoters inducible by reactive oxygen species (ROS), capable of driving the expression of a gene of interest, particularly in a tumor cell. More particularly, it refers to promoters inducible by reactive oxygen species, that may be used to drive the expression of a gene of interest, such as a therapeutic gene, or a reporter gene for use in image diagnosis. The promoters comprise at least a fragment of a promoter sequence responsive to said reactive oxygen species, and corresponding to a gene highly expressed in cancer cells, wherein the fragment of the promoter sequence responsive to reactive oxygen species (ROS) is selected from the group of: the VE element of the VEGF promoter, the E6 element of the promoter of the EGR-1 gene, the MMP-1 element and a chimeric promoter containing an E6 element and a VE element. It also provides vectors carrying a human therapeutic or non therapeutic gene of interest, operably linked to said promoter sequence and compositions comprising the same.

Promoter inducible by reactive oxygen species and vector comprising the same

An isolated DNA sequence corresponding to a region of the SPARC gene human promoter from base pair &#x2212;513 to base pair +35 capable of driving the expression of a heterologous gene of interest, that can be associated to any other promoter sequence, such as radiation responsive sequence, hypoxia responsive sequence and free-radical responsive sequence. The invention also provides constructs and DNA recombinant expression viral vectors, comprising the isolated sequence of the SPARC gene human promoter and at least one heterologous gene operably linked thereto, wherein the promoter sequence drives the expression of the at least one heterologous gene in tumor cells. Pharmaceutical compositions and a method for treating tumors are also provided.

Isolated DNA fragment of the SPARC human promoter and its use for driving the expression of an heterologous gene in tumor cells

Compositions and methods are described that decrease or inhibit osteonectin activity in tumor cells, including cancer cells. The cells cease to be tumor-like, or become less tumor-like. Pharmaceutical composition and therapies based thereon are also described.

Compositions and methods for tumour therapy

Growing community of inventors

Buenos Aires, Argentina

Osvaldo Podhajcer